United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals usa inc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of human milk is about 13 meq per liter. since potassium from oral supplements such as potassium chloride extended-release tablets becomes part of the body potassium pool, as long as body potassium is not excessive, the contribution of potassium chloride supplementation should have little or no effect on the level in human milk. safety and effectiveness of potassium chloride extended-release tablets in children have not been established. clinical studies of potassium chloride extended-release tablets did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy. this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. doses of potassium in patients with cirrhosis produce a larger increase in potassium levels compared to the response in normal patients. based on published literature, the baseline corrected serum concentrations of potassium measured over 3 hours after administration in cirrhotic subjects who received an oral potassium load rose to approximately twice that of normal subjects who received the same load. patients with cirrhosis should usually be started at the low end of the dosing range, and the serum potassium level should be monitored frequently. patients with renal impairment have reduced urinary excretion of potassium and are at substantially increased risk of hyperkalemia. patients with impaired renal function, particularly if the patient is on raas inhibitors or nsaids, should usually be started at the low end of the dosing range because of the potential for development of hyperkalemia [see drug interactions ( 7.2 , 7.3 )] . the serum potassium level should be monitored frequently. renal function should be assessed periodically.

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of human mil

United States - English - NLM (National Library of Medicine)

american health packaging - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - potassium chloride extended-release tablets are indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. potassium chloride is contraindicated in patients on triamterene or amiloride. risk summary there are no human data related to use of potassium chloride extended-release tablets during pregnancy, and animal reproduction studies have not been conducted. potassium supplementation that does not lead to hyperkalemia is not expected to cause fetal harm. the background risk for major birth defects and miscarriage in the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary the normal potassium ion content of h

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - vitamin a palmitate; vitamin d3 = cholecalciferol; alpha-tocopheryl (vitamin e) - parenteral liquid/solution/suspension - vitamin a palmitate vitamin-a active 294.0 mg/ml; vitamin d3 = cholecalciferol vitamin-d3 active 1.25 mg/ml; alpha-tocopheryl (vitamin e) vitamin-e active 50.0 mg/ml - nutrition & metabolism - calf | cattle | lamb | pig - piglet | pigs | sheep | beef | beef calf | boar | bos indicus | bos taurus | bovine | buffalo | bul - vitamin deficiency | prevention & treatment of anae | treatment of basal metabolic d | treatment of debility & anorex

United States - English - NLM (National Library of Medicine)

mayne pharma inc. - vitamin a palmitate (unii: 1d1k0n0vvc) (vitamin a - unii:81g40h8b0t), ascorbic acid (unii: pq6ck8pd0r) (ascorbic acid - unii:pq6ck8pd0r), cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41), sodium fluoride (unii: 8zyq1474w7) (fluoride ion - unii:q80vpu408o) - vitamin a 1500 [iu] in 1 ml - supplementation of the diet with vitamins a, c, d and fluoride 0.25 mg drops also provides fluoride for caries prophylaxis. the american academy of pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. vitamins a, c, d and fluoride 0.25 mg drops provide fluoride in drop form for infants and young children 6 months to 3 years of age, in areas where the drinking water contains children ages 2-3 years where the drinking water contains less than 0.3 ppm of fluoride and for children over 3 years, in areas where the drinking water contains 0.3 through 0.7 ppm of fluoride. each 1.0 ml provides sodium fluoride (0.25 mg fluoride) plus eight essential vitamins and iron. the american academy of pediatrics recommends that infants and young children under 6 months to 3 years of age, in areas where drinking water contains less than 0.3 ppm of fluoride, and; and for children ages 3-6 years, in areas where the dri

United States - English - NLM (National Library of Medicine)

st marys medical park pharmacy - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations, or for patients with whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patient

United States - English - NLM (National Library of Medicine)

direct rx - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations, or for patients with whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 1500 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations, or for patients with whom there is a problem of compliance with these preparations. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern, and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases and if dose adjustment of the diuretic is ineffective or unwarranted supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in suc

United States - English - NLM (National Library of Medicine)

blenheim pharmacal, inc. - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations, or for patients with whom there is a problem of compliance with these preparations. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern, and when low doses of the diuretic are used. serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. in more severe cases and if dose adjustment of the diuretic is ineffective or unwarranted supplementation with potassium salts may be indicated. potassium supplements are contraindicated in patients with hyperkalemia since a further increase in serum potassium concentration in s

Canada - English - Health Canada

quest vitamins a div of purity life health products - vitamin a (retinol palmitate); vitamin d - capsule - 10000unit; 400unit - vitamin a (retinol palmitate) 10000unit; vitamin d 400unit - vitamin a and d